Conference report: Complex clinical, legal, and ethical issues of pregnant and postpartum women as subjects in clinical trials

Journal of Women's Health

Volumn 12, Issue 9, 2003, Pages 857-867

  Goodrum, Linda A ^a   Hankins, Gary D V ^a   Jermain, Donna ^c   Chanaud, Cheryl M ^b,d  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c PFIZER INC   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; PSYCHOTROPIC AGENT; STEROID; UTERUS SPASMOLYTIC AGENT; VACCINE;

ADULT; ARTICLE; ASTHMA; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG SAFETY; FEMALE; FETUS; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH SURVEY; HIGH RISK PREGNANCY; HUMAN; INFECTION PREVENTION; LEGAL ASPECT; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; MEDICAL ETHICS; MEDICAL RESEARCH; MEDICAL SCHOOL; PERINATAL PERIOD; PREGNANCY DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; PUERPERIUM; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; TERATOGENESIS; UNITED STATES;

EID: 0346147021     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/154099903770948087     Document Type: Article

References (53)

1. Shuster E. The Nuremberg Code: Hippocratic ethics and human rights. Lancet 1998;351:974.
2. Women's participation in clinical studies. In: Mastroianni AC, Faden R, Federman D, eds. Washington, DC: National Academy Press, 1994:36.
3. Brennan TA. Proposed revisions to the Declaration of Helsinki - Will they weaken the ethical principles underlying human research? N Engl J Med 1999;341:527.
4. McCarthy CR. Historical background of clinical trials involving women and minorities. Acad Med 1994;69: 695.
5. Legal considerations. In: Mastroianni AC, Faden R, Federman D, eds. Washington, DC: National Academy Press, 1994:128.
6. Gamble VN. A legacy of distrust: African American and medical research. Am J Prev Med 1993;9:35.
7. Merkatz RB. Inclusion of women in clinical trials: A historical overview of scientific, ethical, and legal issues. J Obstet Gynecol Neonat Nurs 1998;27:78.
8. Department of Health and Human Services. Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs. Fed Reg 1993;58: 39406.
9. Mastroianni AC, Faden R, Federman D. Women and health research: A report from the Institute of Medicine. Kennedy Inst Ethics J 1994;4:55.
10. Department of Health and Human Services. Additional DHHS protections for pregnant women, human fetuses, and newborns involved as subjects in research, and pertaining to human in vitro fertilizations. Fed Reg 1998;63:27793.
11. Department of Health and Human Services. Additional protections pertaining to research, development, and related activities involving fetuses, pregnant women, and human in vitro fertilization. Fed Reg 2001;45:56780.
12. United States General Accounting Office. Women's health: Women sufficiently represented in new drug testing, but FDA oversight needs improvement. Women in Clinical Drug Trials Letter 2001;1.
13. Pole M, Einarson A, Pairaudeau N, Einarson T, Koren G. Drug labeling and risk perceptions of teratogenicity: A survey of pregnant Canadian women and their health professionals. J Clin Pharmacol 2000;40: 573.
14. Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: A meta-analytical review of epidemiological studies. Psychol Med 2000;30:89.
15. Koren G, Bologa M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol 1989;160:1190.
16. Kass NE, Taylor HA, Anderson J. Treatment of human immunodeficiency virus during pregnancy: The shift from an exclusive focus on fetal protection to a more balanced approach. Am J Obstet Gynecol 2000;182:856.
17. Weiss S, Vega A, McCloskey C, McFarland B, Corelle C. Prescription drug use during pregnancy among women in KPNW, 1993-1994. FDA Forum on Regulatory Sciences, Bethesda, MD, 1997.
18. Risks to reproduction and offspring. In: Mastroianni AC, Faden R, Federman D, eds. Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies. Vol. 1. Washington, DC: National Academy Press, 1994:175.
19. Department of Health and Human Services, Food and Drug Administration, National Institute for Child Health and Human Development. FDA/NIH Conference: Clinical pharmacology during pregnancy, addressing clinical needs through science, December 4, 2000. Fed Reg 2000.
20. Department of Health and Human Services, Food and Drug Administration, National Institute for Child Health and Human Development. FDA/NIH Conference: Clinical pharmacology during pregnancy, addressing clinical needs through science, December 5, 2000. Fed Reg 2000.
21. Wendel PJ, Ramin SM, Barnett-Hamm C, Rowe TF, Cunningham GF. Asthma treatment in pregnancy: A randomized controlled study. Am J Obstet Gynecol 1996;175:150.
22. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: Establishing pregnancy registries. Fed Reg 1999.
23. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Reviewer guidance: Evaluation of human pregnancy outcome data. Fed Reg 1999.
24. 107th Congress. Safe Motherhood Act for Research and Treatment (Smart Mom Act). Legislative Updates S. 2328/H.R. 4602. 2003. 2-21-2003.
25. Harkin T. Safe Motherhood Act for Research and Treatment. J Am Med Wom Assoc 2002;57:144, 158.
26. Branum AM, Collman GW, Correa A, et al. The National Children's Study of Environmental Effects on Child Health and Development, Environ Health Perspect 2003;3:642.
27. Concept paper on pregnancy labeling: Summary of comments from a public hearing and model pregnancy labeling based on recommendations. Preg-labeling Hearing Summary, 1999.
28. Merkatz RB, Temple R, Sobel S, Feiden K, Kessler DA. Women in clinical trials of new drugs - A change in Food and Drug Administration policy. N Engl J Med 1993;329:292.
29. Caschetta MB, Chavkin W, McGovern T, Kessler DA, Merkatz RB, Temple R. FDA policy on women in drug trials. N Engl J Med 1993;329:1815.
30. Schwetz BA. Reproductive and developmental toxicology. FDA, 2003.
31. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: Considerations for reproductive toxicity studies for preventive vaccines for infectious disease indications. Fed Reg 2000.
32. U.S. Department of Health and Human Services and Food and Drug Administration. Draft guidance for reviewers on the integration of study results to assess concerns about human reproductive and developmental toxicities. Fed Reg 2001;66:219.
33. Fredericksen MC. Physiologic changes in pregnancy: Effect on drug disposition. FDA Center for Drug Evaluation and Research, 2000.
34. Wang Y, Livingston E, Patil S, et al. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: An AIDS Clinical Trials Group study. J Infect Dis 1999;180:1536.
35. Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol 2001; 184:153.
36. Misri S, Burgmann A, Kostaras D. Are SSRIs safe for pregnant and breastfeeding women? Can Fam Phys 2000;46:626.
37. American Academy of Pediatrics. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics 2000;105: 880.
38. Wisner KL, Gelenberg AJ, Leonard H, Zarin D, Ellen F. Pharmacologic treatment of depression during pregnancy. JAMA 1999;282:1264.
39. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: A meta-analysis. Lancet 2000;355:87.
40. Magee LA, Elran E, Bull SB, Logan AG, Koren G. Risks and benefits of β-receptor blockers for pregnancy hypertension: Overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol 2000;88:15.
41. Barrett C, Richens A. Epilepsy and pregnancy: Report of an Epilepsy Research Foundation Workshop. Epilepsy Res 2003;52:147.
42. Morrow JI, Craig JJ. Anti-epileptic drugs in pregnancy: Current safety and other issues. Expert Opin Pharmacother 2003;4:445.
43. Guenther L. Skin drugs in pregnancy - Which ones to use? Dermatol Nurs 1997;9:233, 265.
44. Einarson A, Mastroiacovo P, Arnon J, et al. Prospective, controlled, multicentre study of loperamide in pregnancy. Can J Gastroenterol 2000;14:185.
45. Janssen N, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000;160:610.
46. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized controlled trials. N Engl J Med 1997;337:536.
47. Hall JK. Exclusion of pregnant women from research protocols: Unethical and illegal. IRB: A Review of Human Subjects Research 1995;17:1.
48. The American College of Obstetricians and Gynecologists. Ethical considerations in research involving pregnant women. Wom Health Issues 1999;9:194.
49. Robertson J. Ethical issues related to the inclusion of pregnant women in clinical trials. In: Mastroianni AC, Faden R, Federman D, eds. Woman and Health Reserch: Ethical and Legal Issues of Including Women in Clinical Studies. Vol. 2. Washington, DC: National Academy Press, 1994:18.
50. Reisman EK. Product liability - What is the current situation and will it change (and how) when more women are included in studies? Washington, DC: Food and Drug Law Institute, 1992.
51. A charter for ethical research in maternity care. Nurs Ethics 1998;5:256.
52. Kass NE, Taylor HA, King PA. Harms of excluding pregnant women from clinical research: The case of HIV-infected pregnant women. J Law Med Ethics 1996;24:36.
53. Silverman WA. Human experimentation in perinatology. Clin Perinatol 1987;14:403.